Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis

Rhea-AI Summary

Global Cord Blood Corporation (NYSE: CO) has expressed optimism following Cellenkos, Inc.'s announcement that the FDA has cleared its Investigational New Drug (IND) application for CK0804. This therapy is intended for patients with myelofibrosis who have not responded adequately to ruxolitinib. CEO Ting Zheng praised this development as potentially transformative for myelofibrosis treatments. GCBC, based in China, specializes in cord blood collection and stem cell services.

Positive

• FDA clearance of Cellenkos' IND application for CK0804, indicating progress in myelofibrosis treatment.
• Potential for transforming treatment options for patients with suboptimal responses to current therapies.

Negative

• None.

HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib. Details related to this news can be found via the following Cellenkos news announcement:

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis (prnewswire.com)

Ms. Ting Zheng, Chief Executive Officer and Chairperson of GCBC commented, "The Global Cord Blood team is encouraged by the above news announced by CLNK which highlights a potentially transformative treatment for myelofibrosis patients. We congratulate CLNK team on this development."

About Global Cord Blood Corporation

Global Cord Blood Corporation is an umbilical cord blood banking operator serving multiple regions in China. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com. 

For more information, please contact:

Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com 

ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com

View original content:https://www.prnewswire.com/news-releases/global-cord-blood-corporation-announced-cellenkos-receives-fda-clearance-of-ind-application-for-ck0804-as-add-on-therapy-to-ruxolitinib-for-the-treatment-of-myelofibrosis-301569662.html

SOURCE Global Cord Blood Corporation

FAQ

What recent FDA approval was announced by Global Cord Blood Corporation?

The FDA cleared Cellenkos' Investigational New Drug (IND) application for CK0804 as an add-on therapy for myelofibrosis.

What is CK0804 targeting and why is it significant?

CK0804 is designed for patients with myelofibrosis who experience a suboptimal response to ruxolitinib, highlighting new treatment avenues.

Who is the CEO of Global Cord Blood Corporation?

Ting Zheng is the CEO and Chairperson of Global Cord Blood Corporation.

What does Global Cord Blood Corporation specialize in?

GCBC specializes in cord blood collection, laboratory testing, and stem cell storage services.